-
公开(公告)号：US08758779B2
公开(公告)日：2014-06-24
申请号：US13377968
申请日：2010-06-24
申请人： Sanjay Mate , Ritesh Kapoor , Inderjeetsingh Huda , Kasturi Roy , Munish Talwar , Girish Kumar Jain
发明人： Sanjay Mate , Ritesh Kapoor , Inderjeetsingh Huda , Kasturi Roy , Munish Talwar , Girish Kumar Jain
IPC分类号： A61K9/28 , A61K9/16 , A61K9/14 , A61K31/381 , A61K9/00
CPC分类号： A61K9/28 , A61K9/0095 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K31/381
摘要： The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof.
摘要翻译： 本发明涉及包含度洛西汀或其药学上可接受的盐的掩味药物组合物。 本发明还涉及制备这种组合物的方法。 本发明还公开了包含度洛西汀或其药学上可接受的盐与一种或多种环糊精或其衍生物的包合物。
-
公开(公告)号：US20120164216A1
公开(公告)日：2012-06-28
申请号：US13377968
申请日：2010-06-24
申请人： Sanjay Mate , Ritesh Kapoor , Inderjeetsingh Huda , Kasturi Roy , Munish Talwar , Girish Kumar Jain
发明人： Sanjay Mate , Ritesh Kapoor , Inderjeetsingh Huda , Kasturi Roy , Munish Talwar , Girish Kumar Jain
IPC分类号： A61K31/381 , A61P25/00 , A61P25/22 , A61K9/48 , A61P25/24
CPC分类号： A61K9/28 , A61K9/0095 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K31/381
摘要： The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof.
摘要翻译： 本发明涉及包含度洛西汀或其药学上可接受的盐的掩味药物组合物。 本发明还涉及制备这种组合物的方法。 本发明还公开了包含度洛西汀或其药学上可接受的盐与一种或多种环糊精或其衍生物的包合物。
-
3.发明申请公开(公告)号：US20110052681A1
公开(公告)日：2011-03-03
申请号：US12865783
申请日：2009-02-06
申请人： Ritesh Kapoor , Sanjay Mate , Munish Talwar , Girish Kumar Jain
发明人： Ritesh Kapoor , Sanjay Mate , Munish Talwar , Girish Kumar Jain
IPC分类号： A61K9/48 , A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/145 , A61K9/1635 , A61K9/2018 , A61K9/2027 , A61K31/275
摘要： The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.
摘要翻译： 本发明涉及包含恩他卡朋或其药学上可接受的盐以及一种或多种糖醇的药物组合物; 其中恩他卡朋与一种或多种糖醇共粉碎。 本发明还涉及制备这种组合物的方法。
-
4.发明授权公开(公告)号：US09289392B2
公开(公告)日：2016-03-22
申请号：US13060109
申请日：2009-08-22
申请人： Ritesh Kapoor , Munish Talwar , Sanjay Mate , Manoj Mashalkar , Girish Kumar Jain , Mandar Kodgule
发明人： Ritesh Kapoor , Munish Talwar , Sanjay Mate , Manoj Mashalkar , Girish Kumar Jain , Mandar Kodgule
IPC分类号： A61K9/48 , A61K9/20 , A61K9/24 , A61K31/198 , A61K31/277
CPC分类号： A61K9/2054 , A61K9/2027 , A61K9/209 , A61K9/28 , A61K31/197 , A61K31/198 , A61K31/277 , A61K2300/00
摘要： There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
摘要翻译： 提供了包含约200mg至约1000mg恩他卡朋或其盐，任选与其它药学上可接受的赋形剂的延长释放药物组合物。 本发明还提供了延长释放的药物组合物，其包含约30mg至约300mg左旋多巴，10mg至约100mg卡比多巴和200mg至约1000mg的恩他卡朋或其盐的三重组合，任选与其它药学上可接受的 赋形剂。 本发明还涉及这种组合物的制备方法。
-
5.发明授权公开(公告)号：US08728517B2
公开(公告)日：2014-05-20
申请号：US12865783
申请日：2009-02-06
申请人： Ritesh Kapoor , Sanjay Mate , Munish Talwar , Girish Kumar Jain
发明人： Ritesh Kapoor , Sanjay Mate , Munish Talwar , Girish Kumar Jain
IPC分类号： A61K9/48 , A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/145 , A61K9/1635 , A61K9/2018 , A61K9/2027 , A61K31/275
摘要： The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.
摘要翻译： 本发明涉及包含恩他卡朋或其药学上可接受的盐以及一种或多种糖醇的药物组合物; 其中恩他卡朋与一种或多种糖醇共粉碎。 本发明还涉及制备这种组合物的方法。
-
6.发明申请公开(公告)号：US20110229561A1
公开(公告)日：2011-09-22
申请号：US13060109
申请日：2009-08-22
申请人： Ritesh Kapoor , Munish Talwar , Sanjay Mate , Manoj Mashalkar , Girish Kumar Jain , Mandar Kodgule
发明人： Ritesh Kapoor , Munish Talwar , Sanjay Mate , Manoj Mashalkar , Girish Kumar Jain , Mandar Kodgule
IPC分类号： A61K31/277 , A61K9/20 , A61K9/48 , A61P25/16
CPC分类号： A61K9/2054 , A61K9/2027 , A61K9/209 , A61K9/28 , A61K31/197 , A61K31/198 , A61K31/277 , A61K2300/00
摘要： There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
摘要翻译： 提供了包含约200mg至约1000mg恩他卡朋或其盐，任选与其它药学上可接受的赋形剂的延长释放药物组合物。 本发明还提供了延长释放的药物组合物，其包含约30mg至约300mg左旋多巴，10mg至约100mg卡比多巴和200mg至约1000mg的恩他卡朋或其盐的三重组合，任选与其它药学上可接受的 赋形剂。 本发明还涉及这种组合物的制备方法。
-
公开(公告)号：US20110086070A1
公开(公告)日：2011-04-14
申请号：US12934122
申请日：2008-09-26
申请人： Munish Talwar , Rahul Dabre , Ritesh Kapoor , Himanshu Verma , Nitin Jain , Girish Kumar Jain
发明人： Munish Talwar , Rahul Dabre , Ritesh Kapoor , Himanshu Verma , Nitin Jain , Girish Kumar Jain
IPC分类号： A61K31/235 , A61K31/192 , A61K9/00
CPC分类号： A61K9/0056 , A61K9/2054 , A61K9/7007 , A61K31/192 , A61K31/235
摘要： The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions.
摘要翻译： 本发明涉及包含大黄酸或双醋瑞因或其盐或酯或前药的口服崩解药物组合物，以及制备该组合物的方法。
-
8.发明授权公开(公告)号：US08709485B2
公开(公告)日：2014-04-29
申请号：US12865745
申请日：2009-02-06
IPC分类号： A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/14 , A61K9/145 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/277
摘要： The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions.
-
9.发明申请Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability 失效恩他卡朋，左旋多巴和卡比多巴的药物组合物具有改善的生物利用度公开(公告)号：US20110091558A1
公开(公告)日：2011-04-21
申请号：US12865745
申请日：2009-02-06
IPC分类号： A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/14 , A61K9/145 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/277
摘要： The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalcvo200®. The invention also relates to processes for making such compositions.
摘要翻译： 本发明涉及包含entacapon，左旋多巴和卡比多巴或其盐与一种或多种糖醇的组合的单一口服剂量药物组合物，其中恩他卡朋与一种或多种糖醇共粉碎。 本发明的组合物显示出以商品名Stalcvo 200销售的市售的恩他卡朋，左旋多巴和卡比多巴组合制剂的生物等效性。 本发明还涉及制备这种组合物的方法。
-
10.发明授权Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability 有权恩他卡朋，左旋多巴和卡比多巴的药物组合物具有改善的生物利用度公开(公告)号：US09089485B2
公开(公告)日：2015-07-28
申请号：US14194685
申请日：2014-03-01
IPC分类号： A61K9/14 , A61K9/20 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/277 , A61K9/16
CPC分类号： A61K9/14 , A61K9/145 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/277
摘要： The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions.
摘要翻译： 本发明涉及包含恩他卡朋，左旋多巴和卡比多巴或其盐与一种或多种糖醇的组合的单一口服剂量药物组合物，其中恩他卡朋与一种或多种糖醇共粉碎。 本发明的组合物显示出以商品名Stalevo200销售的市售的恩他卡朋，左旋多巴和卡比多巴组合制剂的生物等效性。 本发明还涉及制备这种组合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.024 秒)
